Remove Licensing Remove Pharmaceutical Companies Remove Trials
article thumbnail

Medicinal cannabis: Why more clinical trials and better access is needed

Drug Discovery World

Big pharma is helping to shape the focus The good news is that clinical trials are on the increase and market education is upping pace. Large pharmaceutical companies are cautiously picking their spots as well. This data is proving useful in testing hypotheses before starting any clinical trials.

article thumbnail

Pfizer launches Phase III trial for Lyme disease vaccine  

Drug Discovery World

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . The trial will enrol up to 6,000 participants aged five years and older and will be conducted across 50 sites where Lyme disease is highly endemic. February 2022.

Vaccine 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Avacta Announces License Agreement With POINT Biopharma Inc.

The Pharma Data

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

article thumbnail

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

The Pharma Data

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. Under the terms of the agreement, ImaginAb will supply clinical doses of 89Zr CD8 Immuno-PET agent to Pfizer for use in select oncology clinical trials. LOS ANGELES , Jan.

article thumbnail

Highs and lows of drug repurposing 

Drug Discovery World

It’s why pharmaceutical companies will often spend up to 10 years and upwards of $1 billion before receiving regulatory approval for a drug. This is a stark contrast to the often decade-long projects that pharmaceutical companies undertake to bring a drug to market.

article thumbnail

Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China

The Pharma Data

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

article thumbnail

Synthetic biology: Innovating in drug discovery

Drug Discovery World

Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. In return MaxCyte will receive platform licensing fees and program-related revenue.

Drugs 130